Nuveen购买了生物技术公司Annexon的股份,以防治罕见疾病并增加其保健投资。 Nuveen bought a stake in biotech firm Annexon to target rare diseases and boost its healthcare investments.

Nuveen收购了生物制药公司Acton Inc.的股份,扩大到保健和生物技术。 Nuveen has acquired a stake in biopharmaceutical company Annexon, Inc., expanding into healthcare and biotechnology. 行动针对罕见和严重疾病,重点是未得到满足的医疗需求高的自发免疫和神经退化疗法。 The move targets rare and serious diseases, focusing on autoimmune and neurodegenerative therapies with high unmet medical needs. 虽然财务细节没有披露,但投资反映了Nuveen实现多样化和接触精密医学进步的战略,符合机构对改革生命科学创新感兴趣的更广泛趋势。 While financial details were not disclosed, the investment reflects Nuveen’s strategy to diversify and gain exposure to precision medicine advancements, aligning with a broader trend of institutional interest in transformative life sciences innovation.